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neck paraganglioma, we integrated high-density genome-
wide copy number variation (CNV) analysis with micro-
rNA and immunomorphological studies. gene-centric 
CNV analysis of 24 cases identified a list of 104 genes most 
significantly targeted by tumor-associated alterations. The 
“NOTCH signaling pathway” was the most significantly 
enriched term in the list (P = 0.002 after Bonferroni or Ben-
jamini correction). expression of the relevant NOTCH path-
way proteins in sustentacular (glial), chief (neuroendocrine) 
and endothelial cells was confirmed by immunohistochem-
istry in 47 head and neck paraganglioma cases. There were 
no relationships between level and pattern of NOTCH1/
JAg2 protein expression and germline mutation status in the 
SDH genes, implicated in paraganglioma predisposition, or 
Abstract Head and neck paragangliomas, rare neoplasms 
of the paraganglia composed of nests of neurosecretory and 
glial cells embedded in vascular stroma, provide a remark-
able example of organoid tumor architecture. To identify 
genes and pathways commonly deregulated in head and 
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the presence/absence of immunostaining for SDHB, a sur-
rogate marker of SDH mutations. Interestingly, NOTCH 
upregulation was observed also in cases with no evidence of 
CNVs at NOTCH signaling genes, suggesting altered epige-
netic modulation of this pathway. To address this issue we 
performed microarray-based microrNA expression analy-
ses. Notably 5 microrNAs (mir-200a,b,c and mir-34b,c), 
including those most downregulated in the tumors, corre-
lated to NOTCH signaling and directly targeted NOTCH1 in 
in vitro experiments using SH-SY5Y neuroblastoma cells. 
Furthermore, lentiviral transduction of mir-200s and mir-
34s in patient-derived primary tympano-jugular paragangli-
oma cell cultures was associated with NOTCH1 downregu-
lation and increased levels of markers of cell toxicity and 
cell death. Taken together, our results provide an integrated 
view of common molecular alterations associated with head 
and neck paraganglioma and reveal an essential role of 
NOTCH pathway deregulation in this tumor type.
Keywords Paraganglioma · Head and neck · NOTCH 
signaling · CNV · MicrorNA · Paraganglioma cell culture
Introduction
Paragangliomas (Pgls), rare, weakly metastatic but inva-
sive neoplasms of the paraganglia, provide an example of 
organoid tumorigenesis from neural crest-derived cells 
belonging to the autonomic nervous system. As paragan-
glia, Pgls can be catecholamine-secreting (chromaffin), 
mostly thoraco-abdominal (including pheochromocyto-
mas), or non-chromaffin, mostly in the head and neck [15, 
32]. Head and neck Pgls account for about 0.6 % of all 
head and neck tumors, usually present between the 4th and 
6th decades of life, and mostly arise from paraganglia at 
the carotid bifurcation, in or around the jugular bulb, in the 
cervical tract of the vagus, or within the temporal bone. 
These Pgls cause important morbidity and are potentially 
lethal, due to the anatomic region of onset [32].
At least one-third of all Pgls have a hereditary basis, 
often blurred by incomplete penetrance or imprinting [18]. 
The susceptibility genes include SDHA, SDHB, SDHC, 
SDHD, and SDHAF2, encoding mitochondrial complex II 
components; and, with lower frequencies, VHL and PHD2 
(EGLN1), that regulate HIFα; the MYC regulator MAX; 
RET, implicated in glial neurotrophic signaling; NF1, 
which controls glial tumorigenesis; TMEM127, associated 
with mTOr signaling, and KIF1Bβ, involved in mitochon-
drial transport and apoptosis [6, 8, 18, 25, 39, 47].
This genetic heterogeneity contrasts with the substan-
tially monotonous tumor phenotype, which mimics para-
gangliar histoarchitecture. In fact, Pgls are organized in 
interconnected cell clusters (“zellballen”), composed of 
neurosecretory (chief) cells encircled by glial (sustentacu-
lar) cells, embedded in angiomatous stroma [32]. At the 
somatic level, the molecular pathways involved in Pgl are 
poorly defined [9, 18].
Our goals were to identify candidate molecular 
pathway(s) commonly affected by genomic alterations 
in head and neck Pgls, characterize the expression pat-
terns of the pertinent gene products and assess the possible 
involvement of microrNAs in their deregulation.
Patients and methods
Cases and controls
The study was approved by the Bioethical Committee of G. 
d’Annunzio University. Blood and tumor samples were from 
consenting consecutive patients operated at the Gruppo Oto-
logico clinic, Piacenza, Italy. Only one patient reported Pgl 
family history, only one was positive for metastases (regional 
lymph nodes). Samples for nucleic acid analyses were stored 
at −80 °C in rNAlater (Qiagen). Fresh samples were also 
obtained for immunofluorescence (IF), electron microscopy 
(eM) and cryoimmuno-electron microscopy (cryo-IeM). 
Overall, 28 cases with 29 tumors (one patient was affected 
with two synchronous Pgls) yielded nucleic acids adequate 
for the study (Supplementary Table 1, Online resource 1). 
Based on quality/quantity of nucleic acids, 23 cases, with 
24 independent tumors, were selected for CNV analysis, 14 
samples from 13 independent tumors were used for mirNA 
expression profiling and 16 samples from 15 independent 
tumors for quantitative reverse-transcriptase real-time (qrT-
PCr) (two distinct samples from tumor 33PT were analyzed 
in these assays). One tumor (case PTJ64) was used to estab-
lish primary cultures of Pgl cells. Formalin-fixed, paraffin-
embedded (FFPe) tissue blocks qualitatively and quantita-
tively adequate for standard immunohistochemistry (IHC) 
could be retrieved for 22 prospectively collected tumors 
(cases 1PTJ through 64PTJ, Supplementary Tables 1–3, 
Online resource 1). In addition, 25 archival tumors (from 24 
cases, acronyms/r1 through/r24, Supplementary Tables 2 
and 3, Online resource 1) were studied by IHC only. Most 
cases were tympanic or tympano-jugular Pgls (PTs and 
PTJs, Supplementary Tables 1 and 2, Online resource 1), 
that arise from Jacobson’s nerve (JN), the tympanic branch 
of the glossopharyngeal nerve (IX cn), from Arnold’s nerve, 
the auricular branch of the vagus (X cn), or from paragan-
glia of the jugular bulb [32]. JN, removed in the modified 
trans-labyrinthine approach for vestibular schwannoma [43], 
is the only normal tissue histogenetically relevant for head 
and neck Pgl procurable at surgery. Thus, millimeter-sized 
samples of morphologically normal JN from 18 donors were 
used as controls for rNA and mirNA expression studies 
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(Supplementary Fig. 1, Online resource 2; Supplementary 
Table 4, Online resource 1).
Mutational analysis of the SDH genes
germline mutational status (point mutations and large dele-
tions/rearrangements) of the three SDH complex genes 
strongly associated with Pgl development (SDHB, SDHC, 
SDHD) was assessed according to published procedures 
[42, 47] on blood samples of 34 cases (9 analyzed at the 
University of Florence, 25 at Albert-ludwigs-University, 
Freiburg). Mutations in SDHAF2, which may contribute 
to Pgl in patients negative for mutations in SDHB, SDHC 
and SDHD [21], were investigated only in the 9 cases ana-
lyzed at Florence. Furthermore, a large germline deletion/
rearrangement in SDHB was detected by CNV analysis and 
validated by orthogonal assays (as detailed below).
CNV and gene-centric analyses
genomic DNA (gDNA) was extracted using DNeasy Blood 
and Tissue kit (Qiagen), checked by agarose electrophore-
sis, and quantitated by Qubit fluorometer (life Technolo-
gies). Paired gDNAs (200 ng) from blood and tumor were 
processed according to the Infinium assay protocol and 
hybridized on HumanOmni1-Quad BeadChips® (>1 mil-
lion markers, Illumina), for 16 h. BeadChips were scanned 
with Illumina Iscan™ and image intensities were extracted 
and genotyped using Illumina’s genome Studio 2011.1® 
software. The SNP genotyping call rate was >99.0 %, 
indicating high-quality data. Only autosomal SNPs were 
considered [67]. The data were analyzed with an original 
framework for computational pipelines management desig-
nated Leaf [41], that integrates CNV-calling softwares (i.e., 
PennCNV) with custom CNV data mining procedures to 
select the CNVs intersecting coding regions, as described 
in Napolitano et al. [40]. Leaf produced a list of the genes 
most significantly over-represented among those targeted 
by CNVs (P < 0.01 by Fisher’s exact test). This list was 
submitted to the Database for Annotation, Visualization, 
and Integrated Discovery (DAVID), which uses fuzzy clus-
tering to group genes into functionally related, statistically 
ranked classes, based on the similarity of the annotations 
(http://david.abcc.ncifcrf.gov) [24].
Orthogonal validation of the CNV hits
Commercial real-time qPCr assays (life Technolo-
gies) were used to validate the CNVs in the JAG2, HES5, 
CTBP1, AKIRIN1, IDUA and PHACTR4 genes. each 
qPCr contained the FAM-labeled TaqMan probe for the 
gene of interest and the VIC-labeled TaqMan probe for 
the rNaseP reference (4403328, life Technologies). each 
qPCr plate included three no template controls. The rela-
tive gene copy numbers were calculated according to man-
ufacturer’s instructions. The Ct values were normalized 
versus the reference Ct (Ct) and the Ct method was 
computed using the mean of the normal samples as calibra-
tor. The CNVs targeting NOTCH1, DVL1 and SDHB were 
validated by non-fluorescent multiplex-PCr coupled to 
high-performance liquid chromatography (NFMP-HPlC) 
[14], using primer pairs in the exonic regions of NOTCH1 
(FW: 5′-AgACggCATCAACACggCCTTC-3′, rW: 5′-g 
TgTAgCTgTCCACgCAgTCCg-3′, 135 bp), DVL1 (FW: 
5′-CCAgACTCATCCggAAgCACAAACg-3′, rW: 5′-g 
ACgATgTTgAgggACATggTggAg-3′, 206 bp) and 
SDHB (FW: 5′-CCCgAggAgCCCAgACAgC-3′, rW: 
5′-CCAgCCTTgTCTgggTCCCATC-3′, 82 bp), together 
with a set of primers (FW: 5′-TCAggCTTAgggTAgAg 
gACAATg-3′, rW: 5′-TCTgCTTgTAgggCAACTCg-3′, 
94 bp) targeting PCBD2, chosen as reference gene because 
it showed no CNVs in our dataset and in a previous study 
conducted by quantitative multiplex PCr of short fluores-
cent fragments [29]. The amplifications were obtained with 
24 cycles using a touch-down PCr protocol (denaturation: 
15 s at 95 °C; annealing: 15 s at 66 °C with 0.5 C° decrease 
per cycle; extension: 30 s at 72 °C). The NFMP products 
were analyzed on a semi-automated DHPlC (Wave 1100, 
Transgenomic Inc, Omaha, Ne) under non-denaturing 
conditions. The peak heights and ratios were obtained as 
described [14]. At least two independent experiments, each 
with triplicate determinations, were performed to validate 
the selected CNV hits.
Immunohistochemistry
The Pgl cases were chosen for immunohistochemistry 
(IHC) after revision of all the standard FFPe blocks and 
hematoxylin–eosin-stained sections for sample quality and 
quantity. Overall, 47 FFPe tumors from 46 cases were rated 
as adequate for IHC. These included 22 of the 28 tumors 
that had been prospectively sampled and for which sta-
tus at the relevant NOTCH-related genes was assessed by 
CNV and/or qPCr, and 25 retrospective tumors, for which 
status at the NOTCH-related genes was unknown (Supple-
mentary Table 3, Online resource 1). Immunostaining for 
NOTCH1 (C-20, that recognizes both full-length NOTCH1 
and its cleaved intracellular form, Santa Cruz Biotechnol-
ogy) and JAg2 (Abnova), both diluted 1/50, was performed 
after heat-induced antigen retrieval (100 °C in Tris–eDTA, 
pH 9 for 30 min). To characterize the cellular components 
of the tumors, step sections were incubated with antibodies 
against: the neuroendocrine marker synaptophysin, strongly 
expressed in both sustentacular and chief cells (27g121, 
Novocastra, diluted 1/200, antigen retrieval at 100 °C in 
citrate buffer, pH 6 for 30 min) [32]; the neurosecretory 
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granule protein chromogranin A, highly expressed in chief 
cells (5H7, Novocastra; diluted 1/200, antigen retrieval at 
100 °C in citrate buffer, pH 6 for 30 min) [32]; the Ca(2+)-
binding protein S100, highly expressed in glial tumors 
(NCl-l-S100p, Novocastra, diluted 1/200, antigen retrieval 
by trypsin treatment for 30 min) [32]; the mesenchymal 
intermediate filament vimentin, expressed in immature glia 
and in endothelia (V9, Novocastra; diluted 1/300, antigen 
retrieval at 100 °C in citrate buffer, pH 6 for 30 min) [5, 
36]; the major anti-apoptotic mitochondrial protein BCl2 
(Bcl2/100/D5, Novocastra, diluted 1/30, antigen retrieval at 
100 °C in citrate buffer, pH 6 for 30 min) [65]; and the pro-
liferation marker Ki-67 (MM1, Dako; diluted 1/50, antigen 
retrieval at 100 °C in Tris–eDTA, pH 9 for 30 min) [32].
SDHB IHC, a surrogate marker for mutations in any of 
the Pgl-associated SDH subunit genes [19, 63], was per-
formed using a commercial mouse monoclonal antibody 
(ABCAM ab14714, clone 21A11, diluted 1/3,000, antigen 
retrieval at 100 °C in citrate buffer, pH 6 for 30 min) [19].
For all the study antibodies immunostaining was car-
ried out on 5-μm-thick whole sections with 15 min incu-
bation at room temperature, using a Bond Max Immu-
nohistochemical Stainer® (leica Microsystems, Wetzlar, 
germany). Positive and negative control slides were 
included for each antibody and in each staining batch. 
The controls for non-specific staining included block-
ing with normal secondary serum prior to staining with 
the primary antibody and substitution of normal serum 
or immunoglobulin g in place of the primary antibody. 
The results were evaluated both in terms of percentage 
of positive cells, counted in four high-magnification 
fields (400×, each field estimated to contain 250–400 
cells), and of intensity, scored on a semiquantitative 
scale (0 = no staining; 1 = weak but definitely posi-
tive staining; 2 = moderate staining; 3 = strong stain-
ing). NOTCH1, JAg2, S100 and BCl2 were assessed in 
the three main Pgl cell types (chief cells, sustentacular 
cells and endothelial cells); synaptophysin in chief and 
sustentacular cells together, as these cell types were simi-
larly and strongly labeled (endothelia were negative), 
vimentin in all cell types combined (chief, sustentacular 
and endothelial cells yielded similar staining). Ki67 was 
evaluated in terms of percentage of positively stained 
nuclei (chief and/or sustentacular cells), counted in four 
high-magnification fields. The other routinely assessed 
clinicopathological variables included vascular invasion, 
bone infiltration and atypia.
SDHB immunostaining was ranked positive when show-
ing granular cytoplasmic labeling (a mitochondrial pattern), 
and negative when weak/diffuse or absent, in the presence of 
positive internal controls (macrophages/monocytes and/or 
endothelia) [19, 63]. The IHC results were analyzed by two-
tailed Student’s t test, or Fisher’s exact test, where appropriate.
Immunofluorescence
Tumor and/or tissue samples were fixed in 4 % buffered 
paraformaldehyde (PFA) at 4 °C for 5–10 h, followed by 
2 % PFA at 4 °C until processing. Cells grown in Cul-
tureSlides plates (BD Biosciences) were fixed in 4 % PFA 
for 30 min at 4 °C, washed in PBS at 4 °C and processed 
within 2 days. IF was performed as described [56], using 
the antibodies against NOTCH1, JAg2, chromogranin A, 
vimentin and S100 detailed above and in Supplementary 
Table 3, Online resource 1, plus antibodies to CTBP1 
(BD Biosciences) and to the hematopoietic/endothelial 
markers CD34 and CD31 (Novocastra). Nuclei were 
stained with DAPI (Sigma-Aldrich). The primary anti-
bodies were visualized using goat anti-mouse Igg fluo-
rescein isothiocyanate-conjugated (Alexa 488, life Tech-
nologies) or goat anti-rabbit Igg Texas-red-conjugated 
(Jackson Immuno research laboratories europe). The 
sections or cells were analyzed using an Apotome Axio 
Observer Z1 inverted microscope (Carl Zeiss) equipped 
with an AxioCam Mrm rev.3. Colocalization of signals 
was analyzed with Axio Vision software release 4.6.3 
(Carl Zeiss).
electron microscopy
Samples were fixed in 2 % glutaraldehyde in PBS for 24 h 
at 4 °C, post-fixed in 1 % OsO4 for 2 h, stained for 1 h in 
1 % aqueous uranyl acetate, dehydrated with graded ace-
tones and embedded in epon-812 (electron Microscopy 
Sciences). Semithin sections stained with 1 % methylene 
blue were used to select suitable areas of ultrastructural 
sectioning. Uranyl acetate/lead citrate-stained ultrathin 
sections were examined with a Philips CM10 transmission 
electron microscope (TeM) (FeI).
Cryo-immunoelectron microscopy
Samples were fixed in 2 % PFA/0.2 % glutaraldehyde in 
0.1 M PBS, pH 7.4, for 24 h at 4 °C, then in 2 % for-
maldehyde overnight at 4 °C. Tissue blocks were embed-
ded into 10 % gelatin (Sigma-Aldrich) in 0.1 M PBS, pH 
7.4, solidified on ice, infused in 2.3 M sucrose overnight 
at 4 °C, mounted on aluminum pins and frozen in liquid 
nitrogen. Ultrathin cryosections (60 nm) collected with 
1 % methylcellulose in 1.15 M sucrose were immunola-
beled with primary antibodies to NOTCH1, S100, chro-
mogranin A, and vimentin, as described [56]. Bound anti-
bodies were visualized using goat anti-mouse conjugated 
with 15-nm gold (British BioCell International) or protein-
A conjugated with 10-nm gold (g. Posthuma, Utrecht, 
The Netherlands). Cryosections were analyzed with a 
Philips CM10 TeM.
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MirNA array
Total rNA was purified using mirNeasy Mini Kit (Qia-
gen) and qualitatively checked using experion (Bio-rad 
laboratories) and spectrophotometry. The rNA samples 
were selected based on relative quality index (rQI >4.5). 
MirNA profiling was performed on 14 Pgl samples from 
13 independent tumors (two distinct areas from tumor 33PT 
were analyzed in this assay; Supplementary Table 1, Online 
resource 1) and 13 Jacobson’s nerves (JNs, Supplemen-
tary Table 4, Online resource 1). Because of the generally 
minute sample sizes and of the inherently low rNA yields, 
we were forced to pool the JN rNAs in 5 sets including 
2–5 nerves, each contributing the same rNA quantity. The 
experiments were conducted using the Human v2 Micro-
rNA expression Profiling Kit (1146 human mirNAs, 
>97 % coverage of mirBase v12) and goldengate gT 
Universal BeadChips on an Illumina IScan™ reader. The 
data were processed through Illumina genome Studio sig-
nal filtration and cleaning algorithms. The mirNAs dif-
ferentially expressed between the Pgl and the JN groups 
were identified using the differential analysis function of 
genome Studio (P < 0.05 after FDr adjustment).
real-time quantitative reverse transcription PCr 
(qrT-PCr)
Total rNA from Pgls and JNs was purified using TrIzol 
(Invitrogen) and quantified with Nanodrop 2000 (Thermo 
Scientific). The mirNA sequences were from mirBase 
(http://www.mirbase.org/index.shtml). The stem loop 
rT primers were designed with a modification to include 
the Universal Probe library (UPl) #21 sequence binding 
site [11, 64]. UPl Probe #21 was from the UPl database 
(roche Diagnostics). Oligonucleotides are in Supplemen-
tary Table 5 (Online resource 1). Total rNA (50 ng) was 
retro-transcribed with the TaqMan Micro-rNA reverse 
Transcription Kit (life Technologies). The reactions were 
incubated 30 min at 16 °C, followed by pulsed rT of 60 
cycles at 30 °C for 30 s, 42 °C for 30 s, and 50 °C for 1 s 
[59].
The NOTCH1, JAG2, HES5 and HES1 mrNA refer-
ence sequences from NCBI were used into the UPl Assay 
Design Center software (https://www.rocheappliedscience
.com/sis/rtpcr/upl/index.jsp?id=uplct_030000) to identify 
the primers and the UPl probes (Supplementary Table 5, 
Online resource 1). Total rNA (700 ng) was retro-tran-
scribed with High Capacity cDNA reverse Transcription 
Kit (life Technologies). The real-time PCrs were per-
formed using an Applied Biosystems 7900 instrument. 
MirNA and mrNA levels were measured using Ct (thresh-
old cycle). Target amount, normalized to an endogenous 
reference (RNU6 or ACTB) and relative to a calibrator, is 
given by 2−ΔΔCt and/or 2−ΔCt methods.
Cells
The neuroblastoma cell line SH-SY5Y (ATCC; Crl-
2266) was acquired in 2007 and authenticated in January 
2013 using AmpFlSTr-Identifiler-Plus Kit (life Technol-
ogies). SH-SY5Y cells were cultured in rPMI 1640 (ge 
Healthcare) with 10 % FBS, 2 mM l-glutamine, 100 IU 
penicillin, 100 μg/ml streptomycin. HeK293 cells were 
cultured in DMeM low glucose supplemented with 
10 % FBS, 2 mM l-glutamine, 100 IU penicillin, 100 μg/
ml streptomycin and 50 μg/ml Normocin (Invivogen). 
Primary Pgl cell cultures from a prospectively sampled 
tympano-jugular Pgl case (PTJ64, primary cultures des-
ignated PTJ64p) were established following a procedure 
previously described for primary rat carotid body cultures 
[44]. In brief, ≈0.5 × 0.5 cm Pgl tissue specimens were 
sampled with sterile equipment in DMeM High glucose 
supplied with antibiotics (penicillin, 100 IU; streptomy-
cin, 100 μg/ml; fungizone, 0.25 μg/ml), within 1 min 
from surgical tumor excision, and maintained at 4 °C dur-
ing transport to the laboratory (8 h). The samples were 
enzymatically dissociated as described in Pardal et al. 
[44]. Cells were cultured in DMeM-F12 (gibco), supple-
mented with 20 % FBS and antibiotics as above, at 37 °C, 
5 % CO2.
lentiviral infection
MirNA-expressing lentiviruses (PMIrH200b-429PA-1, 
PMIrH34bcPA-1, System Bioscience) were generated 
using lentivector-based microrNA precursor constructs 
(System Biosciences), according to the manufacturer’s 
instructions. Control lentiviral particles (Cod. SBP-
MIrH000VA1) were purchased from System Biosciences. 
PTJ64p cells were seeded at 3.6 × 104 cells per well in 
12-well plates in complete culture medium and infected at 
a multiplicity of infection (MOI) of 50.
Caspase and toxicity assays
Measurements of caspase activity and of adenylate kinase 
(AK) release were performed using the Caspase-glo 3/7® 
Assay (Promega) and the Toxilight bioassay kit (lonza, 
Walkersville, MD), respectively, according to the manu-
facturer’s protocols, utilizing a VerITAS microplate lumi-
nometer (Turner BioSystems). All values were in triplicate 
and normalized to the controls, both untreated and infected 
with lentiviral control particles (Cod. SBPMIrH000VA1, 
System Biosciences).
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Transfection and luciferase assays
MirNA mimics precursor and negative control were 
from life Technologies (Supplementary Table 6, Online 
resource 1). MirNAs and vectors were transfected with 
lipofectamine 2000 (life Technologies). After 48 h 
cells were collected for protein and rNA extraction. The 
3′-untranslated region (UTr) of NOTCH1 was ampli-
fied using the primers in Supplementary Table 5 (Online 
resource 1) and cloned downstream of renilla luciferase 
in the psiCHeCK2 vector (Promega). Substitutions into 
the mir-200 and mir-34 binding sites of the NOTCH1 
3′UTr were introduced by Quick-Change site-directed 
mutagenesis (Stratagene) (Supplementary Table 5, Online 
resource 1). The firefly luciferase activity of psiCHeK2 
(Promega) was used as a reference. Transfection was con-
ducted in 24-wells plates. each well was co-transfected 
with psiCHeCK2 (400 ng) and mirNA precursor or nega-
tive control (30 pmol) (NC2, life Technologies). Firefly 
and renilla luciferase activities were measured 48 h after 
transfection using the Dual-luciferase report Assay (Pro-
mega). All experiments were replicated and performed at 
least in triplicate.
Immunoblotting
Cells were collected from six-well plates using trypsin-
eDTA and dissolved in lysis buffer (M-Per; Thermo Sci-
entific) supplemented with complete protease (ge Health-
care) and phosphatase (Sigma-Aldrich) inhibitors. After 
electrophoresis and blotting, the primary antibodies (β actin 
4967, Cell Signaling; NOTCH1 552466, BD Pharmingen; 
NOTCH1 C-20, Santa Cruz; Vinculin H-300, Santa Cruz) 
were incubated overnight at 4 °C. The peroxidase-conju-
gated anti-mouse or anti-rabbit antibodies were incubated for 
1 h at room temperature and detected by chemiluminescence 
(Pierce eCl Western Blotting Substrate; Thermo Scientific), 
β-actin or vinculin normalized loading. The digitalized sig-
nals were quantified in the linear range of the scanner using 
ImageJ 64 software (http://imagejdocu.tudor.lu/).
Results
NOTCH signaling is the most significant pathway targeted 
by CNVs
Leaf analysis [41] of the data generated by the Illumina 
Omni 1 array (>106 SNP) from 24 independent primary 
Pgls and paired blood from 23 patients (Supplementary 
Table 1, Online resource 1) revealed a total of 19370 auto-
somal CNV calls (6777 in blood and 12593 in tumors). 
Figure 1 illustrates the chromosomal positions of the 
tumor-associated CNVs, obtained by subtracting the ger-
mline CNVs detected in the paired blood. Chromosomes 
1p, 7p, 11p, 11q, 17p, 17q, 19p, 19q and 22q were more 
densely affected.
To highlight the genes and the molecular pathways most 
frequently targeted by CNVs, we first identified the top 
affected genes, i.e., those showing the highest level of CNV 
concordances among tumors (P < 0.01 by Fisher’s exact 
test). This highlighted 104 genes, of which 67 targeted by 
amplifications, 22 by deletions and 15 by both amplifications 
and deletions (Supplementary Table 7, Online resource 1). 
None of these 104 genes has been previously associated with 
Pgl. Some have been implicated in non-neoplastic diseases 
(e.g., IDUA, top amplified gene, associated to mucopolysac-
charidosis type I) [53], some have unknown functions (e.g., 
TMEM41B, top deleted gene), some are involved in organo-
genesis and oncogenesis (e.g., NOTCH1, master regulator of 
differentiation and tumorigenesis) [50].
We then used the DAVID bioinformatics resources (http://
david.abcc.ncifcrf.gov) to identify the enriched biological 
themes and the functional-related gene groups among the 
top 104 CNV-affected genes. Only the term “NOTCH sign-
aling pathway”, which included NOTCH1, HES5, JAG2, 
DVL1 and CTBP1, was statistically enriched after Bonfer-
roni and Benjamini corrections (P = 0.0020 for both, Sup-
plementary Table 8, Online resource 1). Leaf analysis [41] 
indicated that the 5 NOTCH signaling-related genes were all 
amplified. In addition, 23 of the 48 partially redundant terms 
in the DAVID listing included NOTCH1 or genes related to 
NOTCH signaling, although these terms were not statisti-
cally significant after Bonferroni or Benjamini corrections 
(Supplementary Table 8, Online resource 1).
The copy number assignments obtained with Leaf anal-
ysis were orthogonally validated using NFMP-HPlC or 
qPCr for the 5 NOTCH signaling genes, for IDUA (top 
amplified gene), and for three deleted genes, AKIRIN1, 
PHACTR4 and SDHB. Overall, the orthogonal validations 
of these CNV hits yielded reproducible results (average 
coefficient of variation: 8.17 %, range 0.17–17.4 %). In 
particular, the CNV and the NFMP-HPlC assays were con-
cordant in 77.5 % (NOTCH1), 84.0 % (DVL1) and 95.6 % 
(SDHB) of the tested samples. CNV and qPCr yielded 
concordances of 82.6 % (JAG2), 67.4 % (HES5), 76.6 % 
(CTBP1), 72.3 % (AKIRIN1), 85.1 % (IDUA) and 100 % 
(PHACTR4). The overall average concordance was 82.3 %. 
The orthogonal validation data are provided in Appendixes 
1 and 2, Online resource 3).
NOTCH1 mrNA is overexpressed in paraganglioma 
versus Jacobson’s nerve
To obtain evidence of possible in vivo deregulation, we 
tested whether NOTCH1 mrNA was overexpressed in 
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Pgls compared to control JNs. NOTCH1 expression was 
measured in 16 Pgl samples (two, 33PT-1 and 33PT-2, 
from different areas of the same tumor) and compared to 
expression in 5 JNs. Overall, 10/16 Pgl samples (56 %) 
showed significant NOTCH1 overexpression, with rela-
tive mrNA levels ranging from 2.27 to 15.27 (Fig. 2). 
Four out of nine Pgls that demonstrated NOTCH1 mrNA 
overexpression (i.e., 1PTJ, 4PTJ, 5PC, and 32PT) showed 
NOTCH1 gains in the CNV analysis as well.
expression of NOTCH pathway proteins
Supplementary Fig. 2 in Online resource 2 shows the 
histoarchitecture of Pgl. We investigated three proteins 
belonging to the NOTCH pathway highlighted by CNV 
analysis, i.e., NOTCH1 (receptor), JAg2 (ligand) and 
CTBP1 (signaling coregulator). IHC on FFPe sections 
indicated that NOTCH1 was expressed in the three main 
Pgl cell types (Fig. 3a, b; Supplementary Table 3, Online 
resource 1).
Apotome IF highlighted punctate NOTCH1 labeling 
in the cytoplasm, along the nuclear profiles and inside the 
nuclei of chief, sustentacular and endothelial cells, the 
latter co-expressing CD34 (Fig. 3c). IHC on FFPe sec-
tions showed that JAg2, undetectable in endothelia, was 
expressed in sustentacular cells, including their filamentous 
processes (Fig. 3d, e).
Apotome IF supported these observations (Fig. 3f) and 
also showed high CTBP1, with punctate pattern, in the 
cytoplasm and nuclei of chief, endothelial and sustentacu-
lar cells (Fig. 3g–j). Nuclear CTBP1 was accentuated in 
endothelial cells (identified by CD31 expression; Fig. 3g) 
and strongly colocalized with S100 in sustentacular cells 
(Fig. 3h–j, Supplementary Fig. 3, Online resource 2).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Fig. 1  Positions of the paraganglioma-associated CNVs on the auto-
somal chromosomes. Darker ideograms highlight the chromosomes 
with higher CNV densities (e.g., 1p, 7p, 11p, 11q, 17p, 17q, 19p, 19q 
and 22q). Green bars to the left of the autosomal silhouettes indicate 
losses, red bars to the right gains. Bar lengths are proportional to the 
observed CNV frequencies. Notably, the telomeric regions show fre-
quent gains, even in the chromosomes less densely affected by CNVs 
(e.g., chromosomes 2q, 4p, 5p, 13q, 18q)
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The immunostaining for NOTCH1 and JAg2 in chief, 
sustentacular and endothelial cells was assessed by semi-
quantitative IHC on representative FFPe sections of 47 
Pgls, including 21 tumors evaluated for CNV status 
at NOTCH1 and JAG2 (Supplementary Table 3, Online 
resource 1). Diffuse NOTCH1 immunostaining in 100 % 
of each of the three main Pgl cell types (chief, sustentacu-
lar and endothelial) was observed in all the Pgls examined 
(47/47), but the staining intensities differed significantly, 
in the following descending order: endothelial cells >sus-
tentacular cells >chief cells (Table 1; Fig. 3a, b; Supple-
mentary Table 3, Online resource 1). In fact, NOTCH1 
staining intensity resulted higher in endothelial cells ver-
sus both chief cells and sustentacular cells (in both cases 
P < 0.0001 by independent sample t test, Table 1), and sus-
tentacular cells were also more intensely stained than chief 
cells (P = 0.0067, Table 1). JAg2 was expressed in 41 out 
of the 45 Pgls in which JAg2 IHC could be performed 
(91 %). JAg2 immunostaining intensity was significantly 
higher in sustentacular relative to chief cells (P = 0.0061, 
Table 1; endothelial cells resulted JAg2 negative). Notably, 
high levels of NOTCH1 and JAg2 immunostaining were 
observed also in the Pgls that did not show CNVs at the 
relevant genes (Supplementary Table 3, Online resource 
1).
The same Pgls were immunostained for synaptophy-
sin, chromogranin A, S100, Ki67, vimentin and BCl2. As 
expected [32], all the tumors strongly expressed synapto-
physin (both sustentacular and chief cells), chromogranin A 
(mainly chief cells) and S100 (mainly sustentacular cells). 
BCl2 resulted significantly higher in the sustentacular rel-
ative to both the endothelial and the chief cells (P < 0.001) 
and also in the endothelial versus the chief cells (P < 0.001) 
(Table 1; Fig. 4a, b). given the substantial uniformity of the 
NOTCH1 and JAg2 expression patterns in the tested Pgls, 
no correlations emerged between the immunostaining 
for these proteins and the other variables (Supplementary 
Table 3, Online resource 1 and data not shown).
germline SDH mutations and SDHB 
immunohistochemistry versus NOTCH1/JAg2 expression
Considering that NOTCH signaling activation could be 
related to SDH gene defects, the Pgl cases were analyzed 
for germline SDH mutations and/or tumor-associated loss 
of SDHB expression, a surrogate marker for mutations in 
any of the known Pgl-related mitochondrial complex II 
genes. germline SDH gene mutation analyses, performed in 
34 cases, identified 13 mutation carriers, furthermore CNV 
analysis identified a large germline deletion/rearrange-
ment of SDHB in one additional case (8PTJ, confirmed by 
NFMP-HPlC). The overall frequency of germline muta-
tions in SDHB, SDHC, SDHD and SDHAF2 was 14/35 
(40 %); single gene mutation frequencies are detailed in 
Supplementary Table 9 (Online resource 1). The germline 
SDH mutation frequencies in the clinically relevant sub-
sets of the tested Pgls (Supplementary Table 10, Online 
resource 1) were in substantial agreement with the litera-
ture data [6, 8, 25, 39, 47]. SDH mutation status resulted 
associated to negative SDHB IHC, with 12 SDHB-negative 
tumors out of 14 tumors from identified SDH gene muta-
tion carriers (85.7 %), versus 6 SDHB-negative tumors out 
of 20 tumors that tested negative for SDH genes mutations 
(30 %) (P = 0.0019 by Fisher’s exact test; Supplementary 
Table 9, Online resource 1).
Overall, 21 out of the 45 Pgls that were qualitatively 
adequate for SDHB IHC (46.6 %) resulted SDHB negative 
(Supplementary Tables 2 and 10, Online resource 1). Dif-
ferences in NOTCH1 or JAg2 IHC intensities between the 
SDHB-positive and the SDHB-negative Pgls were not sig-
nificant by two-tailed Student’s t test (Fig. 5; Supplemen-
tary Tables 2, 3 and 11, Online resource 1).
Cellular and subcellular localizations of NOTCH1  
by cryo-IeM
Cryo-IeM confirmed high NOTCH1 expression in the 
sustentacular cells and their elongated processes, identi-
fied by S100 labeling (Fig. 4c–h). Notably, NOTCH1 was 
detected in early endosomal structures (Fig. 4f) and along 
the plasma membrane, particularly at contact sites between 
sustentacular processes and chief cells (Figs. 4f, g; 6a). 
NOTCH1 labeling was also evident in endothelial cells, 
Fig. 2  relative NOTCH1 mrNA levels measured by qrT-PCr in 
16 paragangliomas relative to 5 Jacobson’s nerves. The dashed line 
indicates the average NOTCH1 mrNA level of the 5 Jacobson’s nerve 
samples (C-JN) used as controls. Samples 33PT-1 and 33PT-2 are 
from different areas of the same tumor. The relative NOTCH1 mrNA 
levels were calculated with the 2−ΔΔCt method, using ACTB as refer-
ence. Asterisks indicate significantly higher NOTCH1 mrNA levels 
after unpaired 2-tailed t test. *P < 0.05; **P < 0.01; ***P < 0.001. 
Error bars represent standard deviation
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along the nuclear and the plasma membranes, in endosomes 
and in the endoplasmic reticulum (Fig. 4d).
Cryo-IeM provided ultrastructural support for interpret-
ing the punctate NOTCH1 cytoplasmic staining observed 
by IF (Fig. 6b–d) and the perinuclear labeling detected by 
IHC (Fig. 6e). In fact, regardless of the tumor cell type, 
NOTCH1 strongly labeled the mitochondria, with pref-
erential localization along the mitochondrial membranes 
(Fig. 6a, f, j). Some labeling was also observed in discrete 
nucleoplasmic areas and in correspondence of the nuclear 
membranes, particularly near nuclear pores (Fig. 6f–j). 
Interestingly, the NOTCH1-labeled mitochondria tended to 
Fig. 3  NOTCH1, JAg2 and CTBP1 immunolabeling in paragangli-
oma. a, b exemplify NOTCH1 immunostaining in paraffin-embedded 
sections (different tumors). NOTCH1 is expressed in the three main 
Pgl cell types, i.e., chief, sustentacular and endothelial (100 % for 
each cell type), with distinctly higher intensity in sustentacular (S) 
and, particularly, endothelial (E) cells. Apotome immunofluores-
cence, performed on single focal planes of frozen sections, highlights 
a punctate distribution of NOTCH1 (red) in the cytoplasm, along 
the nuclear profiles and inside the nuclei (arrows) of chief, susten-
tacular and endothelial cells, the latter identified by double labeling 
(green) with CD34 (c). Immunostaining on formalin-fixed, paraffin-
embedded sections shows that JAg2 is diffusely expressed in the 
zellballen, with markedly higher intensity in the sustentacular cells, 
including their cytoplasmic processes (d, e, arrows). These JAg2 
localizations are supported by Apotome immunofluorescence on 
frozen sections, which demonstrates punctate JAg2 labeling in the 
cytoplasm and along the plasma membranes of chief cells (arrows) 
and strong, diffuse cytoplasmic labeling of sustentacular (S) cells (f). 
Apotome immunofluorescence analysis of CTBP1 also shows high 
protein expression, with punctate pattern, in the cytoplasm and, more 
prominently, in the nuclei of all three Pgl cell types (g–j). Notably, 
CTBP1 labeling appears accentuated in elongated nuclei of cells 
expressing the specific endothelial marker CD31 (g, arrows). Strong 
colocalizations of CTBP1 with S100 (yellow) are notable in the 
nuclei of sustentacular cells (h–j). E endothelial cells, S sustentacular 
cells, ZB zellballen. Bars 10 μm. Original single-channel grayscale 
images for the merged colocalizations of CTBP1 and S100 shown in 
h–j are illustrated in Supplementary Fig. 3 (Online resource 2)
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concentrate in perinuclear position (Fig. 6a, f, j), being in 
some cases closely associated to the nuclear membrane, in 
correspondence of nuclear pores and of NOTCH1-labeled 
nucleoplasm (Fig. 6f, j).
mirNAs controlling NOTCH are deregulated in Pgl
Since tumors with or without evidence of CNVs at 
NOTCH1 and JAg2 showed overexpression of the relevant 
gene products, we hypothesized that mirNAs could pro-
vide a complementary mechanism of NOTCH signaling 
deregulation in Pgl. To identify mirNAs that could have a 
role in Pgl, we performed genome-wide mirNA profiling 
in 14 Pgl samples from 13 independent tumors (two dis-
tinct areas from tumor 33PT were analyzed in this assay) 
versus JN control pools (Supplementary Tables 1 and 4, 
Online resource 1). We identified 16 mirNAs significantly 
(P < 0.05) downregulated and 3 mirNAs significantly 
upregulated in Pgls (Table 2).
Next, we validated the mirNA array data by qrT-PCr 
in 10 Pgls, 1 JN and SH-SY5Y cells. The Pearson cor-
relation coefficient (r) was calculated for 11 mirNAs (5 
downregulated and 6 upregulated), chosen irrespectively of 
the P values resulting from microarray analysis (Table 2; 
Supplementary Fig. 4a, b, Online resource 2). The Pear-
son coefficient of correlation between microarray and 
qrT-PCr expression values ranged between 0.17 and 0.95 
(median: 0.85), supporting the reliability of the microarray 
output (Table 2). Notably, mir-503-5p, the most signifi-
cantly upregulated mir in our assay, showed low, non-sig-
nificant correlation (R = 0.168; P = 0.6) and was therefore 
excluded from further studies, although its concordance 
with the upregulation data analysis was greater than 80 %.
remarkably, five of the most downregulated mirNAs, 
including mir-34b-5p, mir-34c-5p, mir-200a-3p, mir-
200b-3p, and mir-200c-3p, were linked to the NOTCH 
pathway, although in different cellular contexts [3, 4, 26, 
31, 70]. None of these mirNAs was affected by CNVs.
Most of the tested Pgls showed marked downregulation 
of mir-34b-5p, mir-34c-5p, mir-200a-3p, mir-200b-3p, 
and/or mir-200c-3p (Supplementary Figure 4a, Online 
resource 2), often co-occurring with genomic amplifi-
cations of NOTCH pathway genes, with the exception of 
32PT, that had no or modest downregulation of the mir-
NAs targeting the NOTCH pathway and showed amplifi-
cation of NOTCH1, JAG2, CTBP1, HES5, DVL1 (CNVs 
detailed in Appendix 1, Online resource 3).
The mir-200 and mir34 gene families target NOTCH1 
and sensitize primary Pgl cells to cell death
The NOTCH1 3′UTr contains predicted binding sites for 
the mir-34 (mir-34ac/34c-5p/34b*/449abc/449c-5p) and 
mir-8 (mir-200bc/429/548a) gene families (http://www.ta
rgetscan.org/vert_61/), that include mirNAs that we found 
downregulated in Pgls (Supplementary Fig. 5, Online 
resource 2). After comparing the list of the predicted mir-
NAs targeting NOTCH1 and the list of the mirNAs down-
regulated in Pgl, we decided to investigate NOTCH1 as 
direct target of mir-34c-5p and mir-200b-3p in the SH-
SY5Y background. Because of the sequence homology, 
we also considered mir-34b* (mir-34b-5p) and mir-
200a (mir-200a-3p), both downregulated, although not 
predicted to target the NOTCH1 3′UTr. In addition, we 
studied mir-200c (mir-200c-3p), because it appears to tar-
get NOTCH pathway components, such as JAG1 and the 
mastermind-like coactivators MAML2 and MAML3 [4], 
although its downregulation in Pgls did not reach statisti-
cal significance (P = 0.0739). None of these mirNAs map 
to the CNV regions detected in the tested Pgl series (data 
not shown).
To test direct interactions with the NOTCH1 3′UTrs, the 
predicted wild-type and mutant mir-200s and mir-34s tar-
get sites of the 3′UTr-NOTCH1 rNA were cloned down-
stream of the psiCHeCK2 renilla reporter. Then, either the 
wild type or the mutant forms of the psiCHeCK2 3′UTr-
NOTCH1 vectors were co-transfected with mirNA mim-
ics into SH-SY5Y cells. Compared to controls, significant 
reductions in the luciferase activity of the psiCHeCK vec-
tor carrying the wild-type NOTCH1–3′UTr were registered 
with mir-200b (~43 %), mir-200c (~29 %), mir-34b* 
Table 1  Independent samples t test analysis of NOTCH1, JAg2 and 
BCl2 immunostaining intensity levels in the three main paragangli-
oma cell types (chief cells, sustentacular cells and endothelial cells)
a
 JAg2 was not expressed in endothelial cells
Cell type gene Mean ± Se P
NOTCH1
Chief 1.85 ± 0.069 0.0067
Sustentacular 2.00 ± 0.08
Chief 1.85 ± 0.069 <0.0001
endothelial 2.78 ± 0.061
Sustentacular 2.00 ± 0.08 <0.0001
endothelial 2.78 ± 0.061
JAg2a
Chief 0.95 ± 0.056 0.0061
Sustentacular 1.18 ± 0.09
BCl2
Chief 0.17 ± 0.09
Sustentacular 1.11 ± 0.09 <0.001
Chief 0.17 ± 0.09
endothelial 0.8 ± 0.09 <0.001
Sustentacular 1.11 ± 0.09 <0.001
endothelial 0.8 ± 0.09
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(~64 %) and mir-34c (~29 %), but not with mir-200a, 
whereas in the mutated clones luciferase activity was not 
significantly downregulated by the tested mirNAs (Fig. 7a, 
b).
To further confirm NOTCH1 as target of mir-200b, 
mir-200c, mir-34b*and mir-34c, NOTCH1 protein levels 
were assessed in SH-SY5Y cells after mirNAs transfec-
tion. expression of the full-length NOTCH1 was reduced 
by mir-200b (~27 %), mir-200c (~38 %), mir-34b* 
(~80 %) and mir-34c (~15 %) at 48 h from transfection, 
but, again, not by mir-200a (Fig. 7c). However, cleaved 
active NOTCH1 (NTM) was reduced also after enforced 
expression of mir-200a in SH-SY5Y cells (Fig. 7c), sug-
gesting the involvement of this mir in NOTCH1 regula-
tion, as already proposed [58, 70]. To corroborate these 
results, we next assessed the mrNA levels of two transcrip-
tional targets of NOTCH1 (HES1 and HES5) at 48 h from 
mirNA mimics transfection. In all the rNA samples tested 
HES1 and HES5 significantly decreased (Fig. 7d). Since 
there are no predicted mir-200s and mir-34s binding sites 
within the 3′UTr of HES1 and HES5, this was most likely 
due to lower NOTCH1 level.
Next, we examined whether the mir-200s and the mir-
34s could induce cell death. Infection with a gFP lentivi-
ral vector expressing either the mir-200s or the mir-34s 
effectively rescued the expression of the candidate mir-
NAs in PTJ64p, a primary human Pgl cell culture that 
we developed from a tumor showing downregulation of 
the mir-34s and mir-200s by qrT-PCr (Supplementary 
Fig. 6a, b Online resource 2). More than 75 % of the cul-
tured cells became gFP-positive after infection. ectopic 
expression of the relevant mirNAs in PTJ64p (Supple-
mentary Fig. 6b, Online resource 2) resulted in a clear 
reduction of NOTCH1 protein expression by IF, indicat-
ing that the mirNAs transduced by the lentivirus vector 
were functional (Fig. 8a–l). Importantly, the expression of 
the transduced mirNAs in PTJ64p was associated with 
higher caspase-3 activity (P = 0.0284 for the mir-34s; 
P = 0.0043 for the mir-200s) and higher adenylate kinase 
release (P = 0.0002 for the mir-34s; P < 0.0001 for the 
Fig. 4  BCl2 and NOTCH1 immunolabeling in sustentacular and 
endothelial cells. endothelial (E) and sustentacular (S) cells are 
intensely labeled with BCl2 (a, b). The higher level of NOTCH1 
immunostaining in these same cell types, evidenced by immunohisto-
chemistry on paraffin sections (c), is supported by cryo-immunoelec-
tronmicroscopy, which shows NOTCH1 gold along the endoplasmic 
reticulum, nuclear membrane and endosomes of endothelial cells (d). 
Some labeling is also present within the nuclei (d). The sustentacu-
lar cells and their filamentous processes, that deeply penetrate within 
the tumor cell nests, are identified by S100 immunolabeling using 
both immunohistochemistry and cryo-immunoelectronmicroscopy 
(e, h). These processes are densely labeled with NOTCH1 gold (d, 
g), that localizes particularly along plasma membrane contacts with 
chief cells (f). Where sustentacular processes envelope chief cells, 
NOTCH1-labeled endosomal structures are observable in both cell 
types (asterisks, f). N nucleus, Ne nuclear envelope, er endoplasmic 
reticulum, S sustentacular cell, C chief cell. Bars a–c, e = 20 μm, d, 
f–h = 1 μm
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mir-200s), as compared to the scramble control (Fig. 8m, 
n), suggesting that the candidate mirNAs sensitize primary 
human Pgl cells to death.
Discussion
The genes involved in genetic susceptibility to Pgl have 
been extensively studied, but little is known about the 
molecular pathways that drive Pgl tumorigenesis at the 
somatic level [9, 18]. Previous investigations, that utilized 
low density approaches, such as comparative genomic 
hybridization (CgH) and loss of heterozygosity analy-
sis, revealed frequent deletions of chromosome arms 1p, 
3q and 22q and multiple minimal overlapping regions 
of deletion in at least 16 chromosomes, particularly 1p, 
3q, 11p/q, 17p and 22q, while the most common mini-
mal regions of gain were in 1q, 7p, 12q and 19p [18, 52, 
54]. The existence of recurrent losses and gains in several 
chromosomes suggests that multiple genes are inacti-
vated or activated in Pgls. To shed light on the genes and 
genetic pathways implicated in head and neck Pgl, we 
first relied on high-density genome-wide CNV analysis. 
Our high-resolution analysis was in substantial agreement 
with the CgH- and lOH-based literature and revealed 
multiple recurrent losses or gains in several autosomes, 
with 1p, 7p, 11p, 11q, 17p, 17q, 19p, 19q and 22q more 
densely affected.
Following a gene-centric approach, we next identified 
104 genes that were more frequently (P < 0.01) affected 
by CNVs. gains were more frequent than losses in this top 
genes list. The genes were functionally diverse and had 
never been linked to Pgl.
In the present work we focused on the most over-rep-
resented functional gene cluster, “NOTCH signaling” 
pathway, identified by submitting the list of the 104 genes 
with highly recurrent CNVs to the DAVID tool (http://
david.abcc.ncifcrf.gov). Canonical NOTCH signaling is a 
highly conserved contact-dependent intercellular signaling 
mechanism which, interacting with other molecular net-
works depending on cell/tissue contexts, controls a diversity 
of proliferation/differentiation processes, including embry-
ofetal neurogenesis, gliogenesis and vasculogenesis, as well 
as physiological or pathological neoangiogenesis and glial 
homeostasis in the central and peripheral nervous systems 
[46, 50, 61, 69]. NOTCH signaling has multiple fundamen-
tal roles in cancer, where, among other activities, critically 
regulates stem-like cancer cells and contributes to hypoxia 
responses, epithelial-mesenchymal transition (eMT), angio-
genesis and invasiveness [50, 57]. Both normal neural stem 
cells and stem-like cells of neural tumors require NOTCH 
for modulation of self-renewal versus glial, neuronal and 
Fig. 5  SDHB versus NOTCH1 
immunostaining. A paragangli-
oma showing tumor-associated 
loss of SDHB immunostaining 
(a) is compared to a paragan-
glioma with positive SDHB 
immunostaining (d). Both 
tumors show intense and diffuse 
NOTCH1 labeling (b, d). Bars 
10 μm
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endothelial differentiation [57]. Notably, NOTCH dysregu-
lation is implicated in highly angiogenic neural tumors, 
including glioblastoma and medulloblastoma, the leading 
intracranial cancers in adults and children, respectively [16, 
23, 49, 57], as well as neuroblastoma, major neuronal can-
cer of childhood, which, as Pgl and pheochromocytoma, is 
of paragangliar origin [10].
In the Pgl series genotyped for CNVs the high statisti-
cal significance of the “NOTCH signaling pathway” rested 
on five genes targeted by recurrent amplifications, i.e., 
NOTCH1 (9q34.3), JAG2 (14q32), HES5 (1p36.32), DVL1 
(1p36), and CTBP1 (4p16). These CNVs were confirmed 
using orthogonal assays. NOTCH1, prototype of a family 
with four developmentally regulated and tissue-specific 
members (NOTCH1/4), encodes a transmembrane recep-
tor that, after interaction with cognate ligand(s) expressed 
on adjacent cells, is converted into a transcription factor 
[50]. Signal transduction is initiated by consecutive pro-
teolytic cleavages that free the nuclear-bound NOTCH1 
intracellular domain (NICD1) [50]. NICD1 then forms 
enhancer complexes with tissue-specific transcriptional 
activators. NOTCH1 has been shown to have oncogenic 
roles in glial tumors [57] and its activation may be trig-
gered by several mechanisms, including rearrangements 
and activating mutations [2].
The other NOTCH1 pathway genes targeted by frequent 
copy number gains illuminate a molecular context that may 
constrain NOTCH signaling towards biological effects rel-
evant for Pgl tumorigenesis. JAG2 [38], one of the five 
canonical activators of NOTCH1, is hypoxia-dependent 
and correlates with eMT and invasion [48]. HES5, mem-
ber of the HeS (hairy enhancer of split) family of transcrip-
tion factors, is a well-characterized transcriptional target of 
the NICD1 enhancer complex, implicated in neural stem 
cells induction [22]. DVl1 modulates NOTCH stability 
via gSK-3 inhibition and, by sustaining Wnt/beta-catenin 
signaling, cooperates with the NOTCH pathway in pro-
moting the proliferation and differentiation of neural stem 
Fig. 6  Subcellular localizations of NOTCH1 in paraganglioma. 
Cryo-immunoelectronmicroscopy shows that NOTCH1 strongly 
labels mitochondria, with preferential localization of gold particles on 
mitochondrial membranes (a, f, j). This explains the punctate cyto-
plasmic NOTCH1 staining observed by Apotome immunofluores-
cence in frozen sections (b–d) and the perinuclear NOTCH1 labeling 
often evidenced by immunohistochemistry in paraffin-embedded sec-
tions (e). Some NOTCH1 labeling is also observed in discrete nucleo-
plasmic areas (asterisks) and along the nuclear membranes (f, g), 
mostly near nuclear pores (h–j). Notably, the NOTCH1-labeled mito-
chondria tend to concentrate near the nuclear membrane (a–f), par-
ticularly in correspondence of nuclear pores and of NOTCH1-labeled 
nucleoplasm (f–j). As shown before, NOTCH1 gold particles label 
plasma membrane contacts between sustentacular cells and chief cells 
(a). C chief cell, N nucleus, Ne nuclear envelope, M mitochondrion, 
S sustentacular cell, SG secretory granules. Bars b–e = 10 μm, a, 
f–j = 1 μm
588 Acta Neuropathol (2013) 126:575–594
1 3
cells [17]. Moreover, DVl1 specifically increases NOTCH 
signaling in endothelia, inducing sprouting and altering 
vascular differentiation [13]. CTBP1, a coregulator impli-
cated in cancer and eMT [12], links the transcriptional 
effects of NICD to oxygen and nutrients [60] and to sprout-
ing angiogenesis [51]. In sum, the five NOTCH signaling 
genes amplified in Pgl modulate interconnected pathways 
implicated in the development and cross-talk of neural and 
endothelial cells.
Analysis of NOTCH1 and JAg2 expression by IHC in a 
series of 47 FFPe Pgls, including most of the cases geno-
typed by CNV analysis and a case for which we obtained 
primary cell cultures, provided a further level of evidence 
supporting the key role of NOTCH signaling in Pgls. 
These studies were complemented with IF and cryo-IeM, to 
define the cellular and subcellular localizations of the gene 
products and the relationships with known Pgl-related 
markers. IHC demonstrated NOTCH1 immunostaining in 
all the Pgls analyzed, regardless of the individual or clin-
icopathological characteristics. Furthermore, NOTCH1 
and JAg2 were highly expressed in tumors with or with-
out evidence of CNV at the respective loci. This suggested 
that NOTCH1 signaling is a fundamental Pgl pathway 
and that its activation may involve genomic amplification 
along with other mechanisms. Importantly, within tumors, 
NOTCH1 and JAg2 immunostaining was significantly 
correlated to cell type, being NOTCH1 higher in susten-
tacular relative to chief cells and highest in endothelial 
cells, while JAg2, undetectable in the endothelium, was 
particularly evident in sustentacular cells. In this respect 
the filamentous processes, characteristic of this glial cell 
type, are predicted to greatly increase the JAg2-expressing 
plasma membrane surface. Furthermore, these processes 
establish multiple contacts with the plasma membranes of 
other cells, even at remarkable distance. Thus, sustentacu-
lar cells might amplify JAg2-dependent, contact-mediated 
Table 2  MirNAs differentially expressed in paragangliomas versus Jacobson’s nerves
Illumina ID Gene ID
(miRBase)
Chromosome Ratio PGL/JN P R PR Ref
hsa-miR-34b* hsa-miR-34b-5p 11 0.0829 0.0246 0.95 2E-06 [15]
hsa-miR-34c-5p hsa-miR-34c-5p 11 0.0941 0.0246 0.96 1E-06 [14,15]
hsa-miR-200a hsa-miR-200a-3p 1 0.2055 0.0246 0.93 8E-06 [16,19]
hsa-miR-1 hsa-miR-1 20,18 0.2388 0.0246 - - [17]
hsa-miR-33a hsa-miR-33a-p 22 0.2860 0.0246 - - -
hsa-miR-144* hsa-miR-144-5p 17 0.3224 0.0246 - - [19]
hsa-miR-138 hsa-miR-138-5p 3,16 0.4878 0.0246 - - -
hsa-miR-200b hsa-miR-200b-3p 1 0.2563 0.0321 0.89 9E-05 [16,47]
hsa-miR-20b hsa-miR-20b-5p X 0.3370 0.0321 - - -
hsa-miR-133a hsa-miR-133a 20,18 0.4128 0.0321 - - -
hsa-miR-486-5p hsa-miR-486-5p 8 0.4545 0.0321 - - -
hsa-miR-584 hsa-miR-584-5p 5 0.4749 0.0321 - - -
hsa-miR-17 sa-miR-17-5p 13 0.5364 0.0321 - - -
hsa-miR-429 hsa-miR-429 1 0.2105 0.0422 - - -
hsa-miR-486-3p hsa-miR-486-3p 8 0.2430 0.0422 - - -
hsa-miR-363 hsa-miR-363-3p X 0.5237 0.0422 - - -
hsa-miR-200c hsa-miR-200c-3p 12 0.3623 0.0739 0.89 0.0001 [16,18,47]




3p 7/11 4.3523 0.0321 0.74 0.0055 -
hsa-miR-431 hsa-miR-431-5p 14 4.4003 0.0321 0.85 0.0005 -
hsa-miR-127-5p hsa-miR-127-5p 14 2.5358 0.0852 0.77 0.0033 -
hsa-miR-433 hsa-miR-433 14 3.1868 0.0647 0.77 0.0036 -
hsa-miR-483-3p hsa-miR-483-3p 11 1.8400 0.3215 0.75 0.005 -
The Table shows 16 mirNAs significantly (P < 0.05) downregulated (green) and three significantly upregulated (red). MirNAs whose expres-
sion resulted not significantly different in paragangliomas (PGL) versus Jacobson’s nerve (JN) were used to validate the Illumina array by qrT-
PCr (black). The Pearson coefficient of correlation (R) and its P value (Pr), calculated with the qrT-PCr data, are indicated. The last column 
(Ref) lists the reference studies that link the NOTCH pathway to the considered mirNA
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NOTCH1 activation in the Pgl microenvironment. By 
cryo-IeM membrane contacts between sustentacular and 
chief cells demonstrated immunoultrastructural evidence 
of NOTCH1 internalization in both cell types. remarkably, 
JAg2 immunostaining paralleled the distribution of S100, 
a Ca(2+)-binding protein highly expressed in sustentacular 
cells, that performs pro-inflammatory and trophic functions 
and suppresses P53-dependent apoptosis [35]. This sug-
gests that sustentacular cells may “nurse” chief cells with 
JAg2 in an S100-modulated microenvironment. A major 
role of sustentacular cells in Pgl is consistent with the 
physiologic rat carotid body model, where the sustentacular 
population includes the stem cell component of the para-
ganglion [44].
Fig. 7  NOTCH1 is target of mir-200s and mir-34s. a Putative 
binding sites of mir-34b-5p, mir-200b and mir-200c in NOTCH1 
3′UTrs (TargetScan). Asterisks indicate nucleotides substituted in 
mir-34s and mir-200s predicted target sites to perform the luciferase 
assays. b NOTCH1 3′UTrs regulate luciferase activity dependent on 
mir-200b, mir-200c, mir-34b* and mir-34c-5p in SH-SY5Y cells 
(WT wild type, MUT mutant, P P value). renilla luciferase activity 
was normalized on the firefly luciferase activity of the pSICHeCK2 
vector. c Western blot analysis of NOTCH1 (BD, 552466 and Santa 
Cruz, sc-6014r), β-actin (ACTB) and vinculin (VCl) after micror-
NAs transfection in SH-SY5Y cells; the full-length (Fl, ~300 kDa) 
and NOTCH1 transmembrane fragment (NTM, ~120 kDa) are 
indicated. Cells were collected at 48 h from mirNA transfection. 
Normalization with densitometric analysis is shown. d real-time 
quantitative reverse transcription PCr analysis for the NOTCH1 
transcriptional target genes HeS1, HeS5 and NOTCH1 (*P < 0.05; 
**P < 0.005; ***P < 0.0005, ND not detectable)
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As outlined above, cooperative signaling involv-
ing NOTCH1, JAg2, DVl1 and CTBP1 may represent a 
key pro-angiogenic mechanism in Pgl. In glioblastoma, 
NOTCH signaling was proposed to promote endothelial 
trans-differentiation of tumor cells [16, 23, 57]. A similar 
mechanism might play a role in Pgl, a possibility that 
needs to be tested in further studies. The hypothesis would 
be consistent with evidence, provided in this study, that 
Pgl-associated endothelia are morphologically atypical, 
closely juxtaposed to or intimately admixed with susten-
tacular cells and positive for the cell surface sialomucin 
CD34, an endothelial progenitor marker associated with 
angiogenesis and migration [55]. Moreover, the highest 
levels of immunolabeling for NOTCH1 and for CTBP1, 
a coregulator implicated in NOTCH-induced angiogen-
esis [51], were observed in the nuclei of sustentacular and 
endothelial cells. These cells were also strongly positive 
for BCl2, a transcriptional target of the NOTCH pathway 
[50], which characterizes developmental and tumor-asso-
ciated neoangiogenic endothelium and is implicated in the 
cross-talk between endothelial and cancer cells [28]. The 
immunoultrastructural localizations of NOTCH1, revealed 
by cryo-IeM, included mitochondria and nuclei, key sub-
cellular sites of NICD1 signaling [45]. These localizations 
were observed in sustentacular, chief and endothelial cells, 
supporting NOTCH1 activation in all three cell types. The 
strong mitochondrial immunolabeling, mostly associated 
with the organelle membrane, is particularly interesting, as 
NICD1 was previously shown to inhibit BAX multimeri-
zation, thus upregulating resistance to apoptosis by nutri-
ent-deprivation and oxidative stress [45]. Furthermore, in 
sustentacular and endothelial cells a pro-survival action 
of NICD1 would be boosted by the concomitant overex-
pression of BCl2, observed in this study. A key function 
of mitochondria in intracellular NOTCH1 trafficking, as 
proposed by lee et al. [33], is supported by our ultrastruc-
tural findings in Pgls, strongly suggesting mitochondrial-
nuclear shuttling of NICD1 [33].
Overexpression of the NOTCH signaling-related genes 
JAG1 and HES1 has been previously reported in asso-
ciation with VHL- and SDHx-related Pgls, that typically 
manifest a pseudo-hypoxic signature [7, 37]. Therefore, we 
Fig. 8  Primary Pgl cells infected with lentiviruses transducing mir-
200s and mir-34s show downregulation of NOTCH1 expression and 
increased markers of cytotoxicity and death. Primary paraganglioma 
cell cultures PTJ64p were infected with lentiviral vectors transduc-
ing scramble mir control (scramble, a–d, bar 10 μm), mir-34 clus-
ter (mir-34s, e–h, bar 10 μm) and mir-200 cluster (mir-200s, i–l, 
bar 20 μm). a, e, and i show Apotome light microscopic views of the 
exemplified cells. By Apotome immunofluorescence, ectopic expres-
sion of the mir-34s and mir-200s results in clear reduction of the 
NOTCH1 protein signal (red g for mir-34s, k for mir-200s), only 
in cells expressing green fluorescent protein (gFP, green), which 
marks lentivirally infected cells (f mir-34s; j mir-200s) and not in 
gFP-negative (i.e., non-infected) cells present in the same culture. 
No differences in NOTCH1 expression are apparent in cells infected 
with scramble mir control (gFP-positive) versus non-infected cells 
(gFP-negative) in the same culture (b scramble gFP; c scramble 
NOTCH1). Merged immunofluorescence signals for gFP (green) and 
NOTCH1 (red) are shown in d (scramble mir control), h (mir-34s) 
and l (mir-200s). m Shows the results of the caspase 3/7 assay (Pro-
mega) on the same cells. n Shows the citotoxicity assay of PTJ64p 
cells infected with lentiviral vector transducing scramble mir con-
trol, mir-34s and mir-200s, measured by the adenylate kinase activ-
ity (lonza) in the medium of cultured cells. *P < 0.05; **P < 0.01; 
***P < 0.001. Error bars represent standard deviation
591Acta Neuropathol (2013) 126:575–594 
1 3
addressed the question of whether NOTCH signaling acti-
vation was a general feature of the studied head and neck 
Pgls, or was particularly associated to cases with con-
stitutional SDH gene defects. No differences in NOTCH1 
and JAg2 protein expression were observed in the subset 
of Pgls from ascertained germline SDH mutation carri-
ers compared to cases putatively negative for constitutional 
SDH mutations. Furthermore, we found no differences in 
NOTCH1 and JAg2 protein expression in the subset of 
Pgls showing SDHB stain loss, indicative of mutations in 
SDH subunit genes [19, 63], compared to the SDHB-posi-
tive subset. Based on these data we propose that NOTCH 
signaling activation is a basic feature of head and neck 
Pgl, independent from the presence or absence of consti-
tutional SDH gene defects.
Adler et al. [1] reported that treatment with histone 
deacetylase inhibitors, that upregulate NOTCH signal-
ing, results in decreased growth and hormonal secretion in 
PC12 rat pheochromocytoma cells. This study is not nec-
essarily in contrast with our data. In fact, it is well known 
that NOTCH1 is expressed in neural crest paragangliar 
progenitor cells [27]. In the presently studied human head 
and neck Pgls, the highest levels of NOTCH1, JAg2 and 
CTBP1 were found in cells of endothelial and/or glial phe-
notype. Thus, NOTCH signaling could preferentially drive 
the growth of these Pgl-associated cell types.
Copy number variation (CNV) and immunomorpho-
logical data concur in supporting core role(s) for NOTCH1 
and related genes, yet the evidence of protein overexpres-
sion also in cases with no proof of relevant CNVs implies 
that independent mechanisms back up or replace genomic 
changes as drivers of NOTCH activation. given that trans-
lation of NOTCH mrNAs is negatively regulated by mir-
NAs [26, 34], we hypothesized that mirNA-based mecha-
nisms could contribute to NOTCH1 deregulation in Pgl. 
To identify candidate mirNAs we relied on genome-wide 
mirNA profiling of Pgls relative to structurally normal JN, 
the tissue of origin of tympanic Pgl [32]. We identified a 
microrNA signature strictly correlated to the regulation of 
NOTCH1 and of its signaling pathway in Pgl. We proved 
that the mir-200s and mir-34s directly target NOTCH1 and 
that mir-200a indirectly influences the NOTCH pathway in 
SH-SY5Y cells. These microrNAs are strictly correlated to 
the eMT and P53 pathways [20, 30] and their downregu-
lation allows angiogenic responses [70]. Importantly, the 
mir-34, in addition to targeting NOTCH1, directly inhibits 
BCl2 translation [68]. Thus, in Pgl, downregulation of the 
mir-34 could contribute to the concomitant overexpression 
of NOTCH1 and BCl2, observed in the sustentacular and 
in the endothelial cells. Notably, we show that ectopic over-
expression, by lentiviral transduction, of the mir-200s and 
mir-34s effectively downregulates NOTCH1 in primary cell 
cultures of human tympano-jugular Pgl and significantly 
increases caspase activity and adenylate kinase release. This 
suggests that forced downregulation of NOTCH signaling 
sensitizes primary human Pgl cells to death.
In a previous study, Tombol et al. [62] reported that 
NOTCH signaling is one of the top canonical pathways 
potentially targeted by mirNA-based transcriptional 
repression in recurring pheochromocytomas. This observa-
tion is in contrast with our data, but a number of possibili-
ties may account for the apparent divergence: (1) different 
from Pgls, pheochromocytomas are mostly chromaffin; 
(2) in the study of Tombol et al. [62] the differences in 
mir expression were estimated comparing distinct tumor 
subsets, whereas we compared our head and neck Pgls 
to JN, a histogenetically relevant normal tissue control; (3) 
the mirNA-affected pathways were only bioinformatically 
predicted in pheochromocytomas, whereas we performed 
functional studies to validate our findings.
The mechanisms underlying the reduced expression of 
the five presently reported mirNAs regulating NOTCH1 
remain unclear. As none of these mirNAs were affected by 
CNVs, altered epigenetic regulation, such as aberrant DNA 
methylation or histone modifications, could represent a 
mechanism implicated in their downregulation, a possibil-
ity that will have to be investigated in future studies. Vari-
ous other factors might play a role. JAg2, overexpressed 
in sustentacular cells, suppresses the mir-200 family in 
a murine model of metastatic adenocarcinoma [70]. The 
S100 proteins, also overexpressed in sustentacular cells, 
modulate P53 activity [35], and P53 downregulation would 
bring down the mir-34s and the mir-200s [30]. It should 
be noted that most of the tumors with marked downregu-
lation of mirNAs targeting the NOTCH pathway showed 
also genomic amplifications of molecules in the same path-
way. Therefore, it appears that both CNVs and mirNAs 
play a synergistic role in NOTCH pathway upregulation.
In conclusion, whole-genome CNV analysis, mirNA 
profiling and immunomorphology converge in indicating 
that a NOTCH signaling axis involving angiogenic modu-
lators is commonly activated in Pgl. NOTCH1 signaling 
appears upregulated in all the three main Pgl cell types, 
sustentacular (glial), chief (neuroendocrine) and endothe-
lial, possibly with a leading role of sustentacular cells, 
which overexpress ligand and receptor. NOTCH1 signaling 
is likely to be a key player in organoid Pgl tumorigenesis 
and could be implicated in the resistance to radiotherapy 
and anti-angiogenic agents shown by this tumor type [23, 
66]. The effects of NOTCH blockage should be further 
tested in in vitro and in vivo Pgl models.
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